We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

280 hedge funds and large institutions have $6.17B invested in Jazz Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 74 increasing their positions, 126 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 28

33% more call options, than puts

Call options by funds: $66.1M | Put options by funds: $49.5M

33% more funds holding in top 10

Funds holding in top 10: 1216 (+4)

31% more capital invested

Capital invested by funds: $4.72B → $6.17B (+$1.44B)

12% more funds holding

Funds holding: 249280 (+31)

41% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 126

Holders
280
Holders Change
+31
Holders Change %
+12.45%
% of All Funds
8.13%
Holding in Top 10
16
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+33.33%
% of All Funds
0.46%
New
62
Increased
74
Reduced
126
Closed
28
Calls
$66.1M
Puts
$49.5M
Net Calls
+$16.6M
Net Calls Change
-$5.57M

JAZZ Hedge Fund Activity: Q4 2013 in Review

280 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2013, worth a combined $6.17B — up 31% from $4.72B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new JAZZ positions and 28 closed out — a net gain of 34 holders — while 74 added to existing stakes and 126 trimmed.

The largest buyer was Putnam Investments, adding an estimated $242M. The largest seller was Westpac Banking Corp, cutting an estimated $274M.

  • 280 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2013, up from 249 in Q3 2013.
  • Funds reported $6.17B of Jazz Pharmaceuticals stock for Q4 2013, up 31% quarter-over-quarter.
  • 62 funds opened new Jazz Pharmaceuticals positions in Q4 2013 and 28 closed out, a net change of +34 holders.
  • The largest Jazz Pharmaceuticals buyer in Q4 2013 was Putnam Investments, an estimated $242M added.
  • The largest Jazz Pharmaceuticals seller in Q4 2013 was Westpac Banking Corp, an estimated $274M sold.

Based on aggregated 13F filings for Q4 2013.